HYPR heads into its Q1 2026 earnings report on May 14 riding a remarkable 43% one-month price surge — the question is whether the fundamentals can justify a stock that has nearly doubled year-to-date.
Options traders are tilting decisively bullish into the release. The put/call ratio has collapsed to 0.0245, well below its 20-day average of 0.049 and near the bottom of its 52-week range of 0.0004–0.1364. That's an unusually lopsided call-heavy book for a micro-cap heading into an earnings event — investors are reaching for upside, not buying protection. The RSI has climbed to 70, nudging into overbought territory and reinforcing the picture of a stock that has run hard and fast into the print.
The short-selling community is not pressing the other side. Short interest has dropped 36% over the past month to just 1.1% of the free float — a level too small to carry meaningful squeeze dynamics either way. Borrow costs at 0.65% are near a 30-day low, and the lending market remains loose. Bears are not building a meaningful structural position against the rally.
What bulls and bears actually disagree about is the pace of the commercial ramp. Analysts covering the stock are unanimously constructive, with all three carrying Buy ratings and a mean price target of around $2.03, offering roughly 17% upside to current levels. BTIG initiated coverage on April 29 with a Buy and a $2.00 target, a fresh endorsement that captures the recent momentum. Lake Street has been incrementally raising its target since initiating last year, most recently to $2.50 in March. The company carries estimated revenue of around $20M this year against a projected net loss of $34M — the debate centres on how quickly Hyperfine's portable MRI technology can convert clinical interest into durable, growing orders. Founder and major shareholder Jonathan Rothberg holds over 16% of shares outstanding, aligning long-term interests with shareholders but concentrating the ownership story heavily at the top.
The March 2026 earnings release offers a recent reference point. The stock fell nearly 7% the following day and shed 10% over the subsequent five trading sessions after that print — a reminder that positive analyst sentiment and bullish options positioning do not automatically insulate a pre-revenue-stage device maker from a negative reaction when results disappoint. Tomorrow's print will test whether the commercial trajectory has materially improved enough to validate the 43% run that preceded it.
See the live data behind this article on ORTEX.
Open HYPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
